Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Summit Therapeu ADR (SMMT)

13.17 -0.05 (-0.38%)

05-25 15:59

Open:

13.22

Pre. Close:

13.22

High:

13.3

Low:

12.9691

Volume:

11,969

Market Cap:

215M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

13.387 - 13.515

13.515 - 13.593

Low:

12.696 - 12.865

12.865 - 12.966

Close:

12.976 - 13.251

13.251 - 13.418

Technical analysis  (as of: 2018-05-25 4:39:18 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 22.56     One year: 27.22

Support:

Support1: 12.86    Support2: 10.70

Resistance:

Resistance1: 19.31    Resistance2: 23.30

Pivot:

14.34

Moving Averages:

MA(5): 13.48     MA(20): 14.14

MA(100): 13.00     MA(250): 12.35

MACD:

MACD(12,26): 0.14     Signal(12,26,9): 0.34

%K %D:

%K(14,3): 2.64     %D(3): 3.80

RSI:

RSI(14): 46.92

52-Week:

High: 16.861  Low: 8.8  Change(%): 17.6

Average Vol(K):

3-Month: 3602  10-Days 3358

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
SMMT has closed above bottom band by 37.3%. Bollinger Bands are 233.5% wider than normal. The large width of the bands suggest high volatility as compared to SMMT's normal range. The bands have been in this wide range for 5 bars. This is a sign that the current trend might continue.

Headline News

2018-05-07T11:32:00-04:00
The Market Has Spoken: Buy Sarepta

2018-04-30T13:43:57-04:00
Solid Biosciences moving closer to removal of clinical hold on early-stage study of DMD candidate SGT-001; shares up 6%

2018-04-30T13:23:06-04:00
Capricor launches mid-stage study of DMD candidate CAP-1002; shares up 2%

2018-04-24T08:00:00-04:00
3 Things In Biotech, April 23: Support, Support, And Those Blasted Blood Vessels

2018-04-12T12:53:02-04:00
Summit Therapeutics 2017 Q4 - Results - Earnings Call Slides

2018-04-12T09:15:11-04:00
Dosing underway in early-stage study of Pfizer's DMD candidate

2018-04-11T14:35:15-04:00
Summit Therapeutics (SMMT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow

2018-04-11T13:42:07-04:00
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript

Financial Analysis

Growth

NA

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

NA

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

NA

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

16.40

Shares Float (M)

16.40

% Held by Insiders

% Held by Institutions

82.40

Shares Short (K)

323

Shares Short Prior Month (K)

10

Stock Financials

EPS

-2.100

EPS Est. Current Year

-0.530

EPS Est. Next Year

-1.050

EPS Est. Next Quarter

-0.620

Forward EPS

-1.971

Book Value (p.s.)

16.780

PEG Ratio

Profit Margin

-10.00

Operating Margin

-59.32

Return on Assets (ttm)

-15.6

Return on Equity (ttm)

-223.5

Qtrly Rev. Growth

76.9

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

0.105

Qtrly Earnings Growth

Operating Cash Flow (M)

-20.69

Levered Free Cash Flow (M)

-14.83

atoplab.com

Valuation

P/E

-6.27

P/E Growth Ratio

P/BV

0.78

P/S

297238240.00

P/CF

-10.44

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.